Carlsmed(CARL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Carlsmed
CARL.US
Carlsmed, Inc., a commercial-stage company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
1.347 T
CARL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Goldman Sachs Reaffirms Their Buy Rating on Carlsmed, Inc. (CARL)

    Goldman Sachs has reaffirmed a Buy rating on Carlsmed, Inc. (CARL) with a price target of $18.00, according to analyst David Roman. Roman, a 2-star analyst with a 48.72% success rate, focuses on the Healthcare sector. Additionally, Truist Financial also issued a Buy rating for Carlsmed, while TipRanks reiterated a Hold rating today.

    Tip Ranks·
    US
    CARL
    -1.97%
    Tip Ranks·
    US
    CARL
    -1.97%

    Carlsmed shares are trading higher. The company announced preliminary Q4 and FY25 revenue guidance.

    benzinga_article·
    US
    CARL
    -1.97%
    benzinga_article·
    US
    CARL
    -1.97%

    Carlsmed's preliminary Q4 revenue rises 61% to $15.2 mln

    Carlsmed's preliminary Q4 2025 revenue increased by 61% year-over-year to $15.2 million, with full-year revenue rising 86% to $50.5 million. The company added 101 new surgeon users, a 61% increase, contributing to this growth. Carlsmed anticipates further adoption of its aprevo platform in 2026 and aims for operational excellence. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $20.00, reflecting a potential upside of 57.6% from its recent closing price of $12.69.

    Reuters·
    US
    CARL
    -1.97%
    Reuters·
    US
    CARL
    -1.97%

    Carlsmed | 8-K: FY2025 Revenue: USD 50.5 M

    LB filings·
    US
    CARL
    -1.97%
    LB filings·
    US
    CARL
    -1.97%

    Carlsmed Reports 86% Revenue Growth for Full Year 2025

    Carlsmed Inc. reported preliminary revenue results for Q4 and full year 2025, showing a 61% increase in Q4 revenue to approximately $15.2 million and an 86% increase in full year revenue to about $50.5 million compared to 2024. The company also added 101 new surgeon users in 2025, a 61% rise in its total user base. These results are preliminary and subject to revision until the full financial results are filed in the Annual Report on Form 10-K.

    Reuters·
    US
    CARL
    -1.97%
    Reuters·
    US
    CARL
    -1.97%
    © 2026 Longbridge｜Disclaimer